Cutaneous Adverse Events during Vemurafenib Therapy

2014 ◽  
Vol 18 (4) ◽  
pp. 223-228 ◽  
Author(s):  
Shivani Felicia Chandrakumar ◽  
Jensen Yeung
Keyword(s):  
Side Effects ◽  
Adverse Events ◽  
Squamous Cell ◽  
Case Series ◽  
Stage Iv ◽  
Therapeutic Benefit ◽  
Braf V600e ◽  
Life Threatening ◽  
The Common ◽  
Dose Reductions

Background: Vemurafenib, an oral agent that selectively targets the BRAF V600E mutation, has recently emerged as the mainstay of treatment in patients with BRAF-positive stage IV melanoma. A spectrum of cutaneous adverse events has been associated with vemurafenib, ranging from benign rashes to malignant side effects such as keratoacanthoma and squamous cell carcinoma. Objective: In this article, we review clinical data regarding the frequency and severity of the common dermatologic side effects associated with vemurafenib; case series and noncontrolled studies evaluating the safety of vemurafenib therapy are used to further characterize these adverse events. Conclusion: Benign vemurafenib-induced side effects generally tend not to be severe or life threatening, with most patients managed by dose interruptions, dose reductions, or topical therapies. Squamous cell carcinomas and keratoacanthomas associated with vemurafenib therapy are easily treated by simple excision of the lesion without discontinuation of vemurafenib. Thus, awareness of potential adverse events coupled with routine dermatologic assessment and timely management will allow for optimal therapeutic benefit in patients receiving vemurafenib therapy.

Proton Pump Inhibitors in 2021: Pros, Cons, and Everything in Between

2021 ◽  
pp. 263451612110217
Author(s):  
Joshua A. Sloan ◽  
Philip O. Katz
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Adverse Events ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Drug Class ◽  
Life Threatening

The medical and lay literature has exploded with reports of adverse events associated with proton pump inhibitors over the last 10 to 15 years. The dissemination of these reports to patients and clinicians have created substantial concerns regarding what has been an exceptionally valuable drug class, dramatically improving patient quality of life, and in many cases preventing life threatening side effects of other medication. Patients are more frequently seeking to avoid these medications, and practitioners are reducing or discontinuing them to the patient’s detriment due to a misunderstanding of the data. This review will discuss the data regarding the most commonly publicized adverse events and attempt to put them in perspective.

scholarly journals Ovarian Torsion Presentation, Treatment and Iatrogenic Surgical Management

2021 ◽  
pp. 70-76
Author(s):  
Sheema Sabahath ◽  
Hussain Salah AL Sinan ◽  
Asalah Tariq Alsaigh ◽  
Rawan AlSalamah AlFadhli ◽  
Tahani Salman Al Mansour ◽  
...  
Keyword(s):  
Blood Flow ◽  
Abdominal Pain ◽  
Side Effects ◽  
Adverse Events ◽  
Surgical Intervention ◽  
Clinical Manifestations ◽  
Ovarian Torsion ◽  
Adult Females ◽  
Uterine Ligaments ◽  
Life Threatening

Ovarian torsion is among the gynecological life-threatening conditions that may require urgent surgical intervention among the appearance of clinical manifestations. The most common clinical manifestations include severe abdominal pain, nausea extending to vomiting. The ovarian torsion is not limited to children only. However, it can also occur in adult females, either pregnant or non-pregnant. The etiology of the disease tends to be related to the weakness of the uterine ligaments or malpositioning of it due to known and unknown causes. Despite that, the surgical intervention is needed to release the torsion. Sometimes, it can lead to adverse events or side effects such as decreased blood flow to the surrounding structures. Which by role may lead to unpleasant complications and clinical manifestations of hemorrhage and shock. In this article, we reviewed the topic of ovarian torsion from different aspects, including the definition, causes, clinical evaluation, and clinical management and its common complications.

scholarly journals Prognostic Factors in Paranasal Sinus Squamous Cell Carcinoma and Adenocarcinoma: A SEER Database Analysis

2018 ◽  
Vol 80 (03) ◽  
pp. 258-263 ◽  
Author(s):  
Sumit Jain ◽  
Yan Li ◽  
Edward C. Kuan ◽  
Bobby A. Tajudeen ◽  
Pete S. Batra
Keyword(s):  
Squamous Cell Carcinoma ◽  
Multivariate Analysis ◽  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Paranasal Sinus ◽  
Squamous Cell ◽  
Case Series ◽  
Stage Iv ◽  
Retrospective Case ◽  
Female Ratio

Background Outcome studies on sinonasal malignancy are limited to retrospective case series, often with inclusion of diverse histology and short follow-up. The objective of this study was to identify key predictive variables that independently impact survival for paranasal sinus squamous cell carcinoma (SCC) and adenocarcinoma (AC) and to compare these variables in the context of these two distinct clinicopathologic entities. Methods: Analysis was conducted using the Surveillance, Epidemiology, and End Results database from 1973 to 2012 to identify key variables that impact survival for SCC and AC. Results A total of 3,714 cases were included. There were 2,895 SCC cases and 819 AC cases. The mean age at diagnosis was 64.1 years. The male to female ratio for SCC and AC was 1.85 and 1.04, respectively. Patients with SCC and AC were most often diagnosed with stage IV disease in 61.8 and 63.4% of cases, respectively. The majority of patients received combined surgery and radiation (52% for SCC and 43.1% for AC). For SCC, increased age (p < 0.001) and stage (p < 0.001) were negative predictors, and surgery improved survival (p < 0.001) on multivariate analysis. For AC, prognostic factors associated with worse survival include increased age (p < 0.001) and grade (p < 0.001) on multivariate analysis. Overall survival was significantly higher in AC compared with SCC at 5 years (p = 0.001). Conclusion SCC and AC of the paranasal sinuses are both aggressive malignancies with poor survival. For both histological subtypes, increased age predicts worse survival and grade also closely links to survival in AC. These data have important potential implications for treatment planning and pretreatment counseling.

scholarly journals Risks associated with oral deferiprone in the treatment of infratentorial superficial siderosis

2019 ◽  
Vol 267 (1) ◽  
pp. 239-243 ◽  
Author(s):  
Y. Sammaraiee ◽  
G. Banerjee ◽  
S. Farmer ◽  
B. Hylton ◽  
P. Cowley ◽  
...  
Keyword(s):  
Side Effects ◽  
Case Series ◽  
Iron Chelator ◽  
Superficial Siderosis ◽  
Neutropenic Sepsis ◽  
Favourable Safety ◽  
Favourable Safety Profile ◽  
Life Threatening ◽  
The Mean ◽  
Mean Time

Abstract Objective Deferiprone is an iron chelator that has recently been used to treat patients with infratentorial superficial siderosis (iSS). It is considered to have a generally favourable safety profile but concerns have been raised due to the risk of agranulocytosis. We aimed to evaluate the safety and tolerability of oral deferiprone as a treatment for patients with iSS. Methods We present a case series of 10 consecutive patients presenting with classical iSS treated with deferiprone. Results Ten patients were followed up for a mean period of 2.3 years (range 0.5–5.5 years). Four patients (40%) were withdrawn from treatment because of treatment-related side effects. The reasons for treatment discontinuation were neutropenic sepsis (n = 3) and fatigue (n = 1). In 2 out of the 3 cases of neutropenic sepsis, patients initially developed neutropenia without sepsis. The mean time to neutropenic sepsis following deferiprone was 1.2 years (range 0.3–2.5) with mean neutrophil count of 0.4 (range 0.3–0.5). Six patients (60%) reported no change in neurological function while on treatment, and four patients (40%) reported that their condition deteriorated. Conclusions Deferiprone was poorly tolerated, with 40% of patients withdrawing from treatment, most commonly due to neutropenic sepsis, after an average of 2 years on treatment. This study increases the number of reported cases of agranulocytosis in patients with iSS treated with deferiprone. Clinicians treating iSS patients with deferiprone should be aware that this drug has a potentially life-threatening side effect of neutropenic sepsis, and should ensure that appropriate haematological monitoring is in place.

scholarly journals Management of rheumatic complications of immune checkpoint inhibitor therapy – an oncological perspective

Rheumatology ◽  
2019 ◽  
Vol 58 (Supplement_7) ◽  
pp. vii29-vii39 ◽  
Author(s):  
Neil M Steven ◽  
Benjamin A Fisher
Keyword(s):  
Adverse Events ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitors ◽  
Cancer Control ◽  
Myasthenic Crisis ◽  
Life Threatening ◽  
Checkpoint Inhibitor Therapy ◽  
The Common ◽  
Risk And Benefit

Abstract Immune checkpoint inhibitors (CPIs) are an effective treatment for many cancers but cause diverse immune-related adverse events (IrAEs). Rheumatological IrAEs include arthralgia, arthritis, tenosynovitis, myositis, polymyalgia rheumatica and sicca syndrome. CPI use can unmask RA as well as causing flares of prior autoimmune or connective tissue disease. Oncologists categorize and grade IrAEs using the Common Terminology Criteria for Adverse Events and manage them according to international guidelines. However, rheumatological events are unfamiliar territory: oncologists need to work with rheumatologists to elicit and assess symptoms, signs, results of imaging and autoantibody testing and to determine the use of steroids and DMARDs. Myositis may overlap with myasthenic crisis and myocarditis and can be life-threatening. Treatment should be offered on balance of risk and benefit, including whether to continue CPI treatment and recognizing the uncertainty over whether glucocorticoids and DMARDs might compromise cancer control.

scholarly journals Rectus Sheath Haematoma Associated with Low Molecular Weight Heparin: A Case Series

2007 ◽  
Vol 89 (3) ◽  
pp. 309-312 ◽  
Author(s):  
J Donaldson ◽  
CH Knowles ◽  
SK Clark ◽  
I Renfrew ◽  
MD Lobo
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Case Series ◽  
Rectus Sheath ◽  
Low Molecular Weight ◽  
Recent Treatment ◽  
Life Threatening ◽  
Benign Nature ◽  
The Common

A report of three cases of spontaneous rectus sheath haematoma within a 1-month period in a single hospital. The common feature was the recent treatment with low molecular weight heparin. In contrast to the perceived benign nature of the classically-described haematoma, the cases described were life-threatening and required aggressive intervention.

Outcomes and toxicities among octogenarians and nonagenarians with colorectal cancer (crc) treated with chemotherapy or concurrent chemoradiation - a single institution study

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 13514-13514
Author(s):  
J. Yu ◽  
N. M. Reddy ◽  
A. Rajput ◽  
J. Smith ◽  
G. Yang ◽  
...  
Keyword(s):  
Median Survival ◽  
Stage Iv ◽  
Kaplan Meier ◽  
Phase Ii Studies ◽  
Metastatic Setting ◽  
Stage Iv Disease ◽  
Life Threatening ◽  
Chemotherapy Dose ◽  
Dose Reductions ◽  
Grade Iii

13514 Background: Chemotherapy is associated with an improved overall survival with acceptable toxicities in patients ≥ 70 years. However, little to no data exists regarding feasibility and tolerability of chemotherapy and/or radiation in CRC patients ≥ 80 years. The purpose of this study was to identify the trends of increased toxicity in this subgroup of patients. Methods: A retrospective study on patients ≥ 80 yrs treated for CRC with either chemotherapy alone or chemoradiation during the period of 1996- 2005 at Roswell Park Cancer Institute was conducted. Survival analysis was performed using the Kaplan-Meier method. Results: 29 patients were identified. 8 patients were diagnosed as having rectal cancer and received combined chemoradiation. 21 patients had colon cancer and received chemotherapy alone either in the adjuvant or metastatic setting. The median age was 82 years (range: 80–93). The median survival for all stages receiving chemo and/or radiation therapy was 37 months (95% CI: 27–53). The median survival for patients with stage IV disease was 6 months (95% CI: 5–33). Grade III/IV GI toxicities were seen in 59% (95% CI: 37–72%) of patients. Grade III/IV hematologic toxicities were seen in 17% (95% CI: 8–37%) of patients. Empiric chemotherapy dose reductions were implemented, starting the first cycle, in 90% (95% CI: 72–96%)of patients. Therapy had to be withheld in 34% (95% CI: 19–52%) of patients by more than 1 week due to toxicities in the first 2 months of treatment. Conclusions: Our study, demonstrates a higher rate of toxicities than previously reported for patients ≥ 70 years. This has occurred despite an initial dose-reduction in the majority of the treated population (90%). Octogenarian and nonagenarian CRC patients experienced a higher rate of GI toxicities during treatment, some of which were life threatening. This data supports the urgent need to conduct prospective studies to identify treatment recommendations for patients ≥ 80. Data from larger elderly phase II studies with median ages < 80 should not be extrapolated to octogenarians and nonagenarians. No significant financial relationships to disclose.

scholarly journals Detect it so you can treat it: a case series and proposed checklist to detect neurotoxicity in checkpoint therapy

2020 ◽  
Author(s):  
Saskia Bolz ◽  
Thivyah Ramakrishnan ◽  
Michael Fleischer ◽  
Elisabeth Livingstone ◽  
Benjamin Stolte ◽  
...  
Keyword(s):  
Adverse Events ◽  
Checkpoint Inhibitor ◽  
Checkpoint Inhibitors ◽  
Case Series ◽  
Transverse Myelitis ◽  
University Hospital ◽  
Life Threatening ◽  
Checkpoint Inhibitor Therapy ◽  
Cancer Types ◽  
Brachial Plexus Neuritis

Abstract Background: Checkpoint inhibitors show impressive and durable responses in various cancer types and provide new avenues for cancer immunotherapy. However, these drugs have a variety of adverse events. Common autoimmune-related adverse effects include fatigue, hepatitis, skin rash, endocrine deficiencies, and colitis. Neurotoxicity has been reported, but its incidence and course remain unclear.Methods: To illustrate the broad spectrum of neurotoxicity, we exemplarily report the neurological adverse events of five patients with melanoma and one patient with differentiated thyroid cancer who received checkpoint inhibitors at Essen University Hospital (Essen, Germany).Results: After treatment with ipilimumab, nivolumab or pembrolizumab, neurotoxic effects included hypophysitis-associated neck pain and headache, Guillain-Barré syndrome, transverse myelitis, acute brachial plexus neuritis, and ocular myasthenia gravis.Conclusions: Checkpoint inhibitor therapy remains a success story; however, neurological immune-related adverse events may cause severe life-threatening conditions. We propose a checklist for the early detection of neurological adverse events during routine clinical treatment to prevent more severe courses of checkpoint inhibitor-induced neurotoxicity.

scholarly journals An analysis of potential costs of adverse events based on Drug Programs in Poland. Pulmonology focus

2014 ◽  
Vol 27 (1) ◽  
pp. 32-36
Author(s):  
Monika Szkultecka-Debek ◽  
Mariola Drozd ◽  
Karina Jahnz-Rozyk ◽  
Nina Kiepurska ◽  
Joanna Mazurek ◽  
...  
Keyword(s):  
Side Effects ◽  
Adverse Events ◽  
Medicinal Products ◽  
Disease Area ◽  
Significant Cost ◽  
The Public ◽  
Polish Society ◽  
Costs Of Treatment ◽  
The Common ◽  
Public Payer

Abstract The project was performed within the Polish Society for Pharmacoeconomics (PTFE). The objective was to estimate the potential costs of treatment of side effects, which theoretically may occur as a result of treatment of selected diseases. We analyzed the Drug Programs financed by National Health Fund in Poland in 2012 and for the first analysis we selected those Programs where the same medicinal products were used. We based the adverse events selection on the Summary of Product Characteristics of the chosen products. We extracted all the potential adverse events defined as frequent and very frequent, grouping them according to therapeutic areas. This paper is related to the results in the pulmonology area. The events described as very common had an incidence of ≥ 1/10, and the common ones ≥ 1/100, <1/10. In order to identify the resources used, we performed a survey with the engagement of clinical experts. On the basis of the collected data we allocated direct costs incurred by the public payer. We used the costs valid in December 2013. The paper presents the estimated costs of treatment of side effects related to the pulmonology disease area. Taking into account the costs incurred by the NHF and the patient separately e calculated the total spending and the percentage of each component cost in detail. The treatment of adverse drug reactions generates a significant cost incurred by both the public payer and the patient.

scholarly journals Safety and Tolerability of a Rapid Transition From Intravenous Treprostinil to Oral Selexipag in Three Adolescent Patients With Pulmonary Arterial Hypertension

2021 ◽  
Vol 26 (5) ◽  
pp. 512-516
Author(s):  
Elizabeth Colglazier ◽  
Angelica J. Ng ◽  
Claire Parker ◽  
Hythem Nawaytou ◽  
Jeffrey R. Fineman
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Side Effects ◽  
Adverse Events ◽  
Pediatric Patients ◽  
Case Series ◽  
Inpatient Setting ◽  
Inpatient Hospitalization ◽  
Adolescent Patients ◽  
Rapid Transition ◽  
Pulmonary Arterial

There is limited published experience with transitioning pediatric patients from parenteral treprostinil to oral selexipag therapy. In addition, published transitions have typically been protracted, taking several weeks to complete. We present a case series of 3 adolescent patients who were transitioned from parenteral treprostinil to oral selexipag over a 5- to 7-day period. Their clinical courses leading up to the transitions are summarized and their outcomes are described. The 3 patients were successfully rapidly transitioned during an inpatient hospitalization without any observed adverse events or prostacyclin-related side effects. We conclude that when indicated rapid transition of parenteral to oral prostacyclin therapy may be performed safely in adolescents in an inpatient setting.

Sign in / Sign up

Export Citation Format

Share Document